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Abstract
Background: The transcription factor, CCAAT enhancer binding protein-b (C/EBPb), is expressed as several distinct
protein isoforms (LAP1, LAP2 and LIP) that have opposing actions in cellular proliferation and differentiation.
Increases in the ratio of LIP/LAP are associated with aggressive, metastatic breast cancer; however, little is known
regarding the molecular mechanisms that regulate LIP expression or the biological actions of an increase in the
LIP/LAP ratio. Metastasis is highly dependent upon the suppression of anoikis and the role of C/EBPb and LIP in
this anchorage-independent, survival process is currently not known in mammary epithelial cells. IGF-1R signaling is
important for the survival of breast cancer cells and crosstalk between IGF-1R and EGFR signaling pathways have
been implicated in the development of more aggressive disease. We therefore evaluated in mammary epithelial
cells whether IGF-1R signaling regulates the LIP/LAP ratio, analyzed the potential interplay between EGFR and IGF-
1R signaling and addressed the biological significance of increased LIP expression in cellular survival and
suppression of anoikis.
Results: Our data provide the first evidence that IGF-1R signaling regulates LIP expression in an EGFR independent
manner to increase the LIP/LAP ratio in mammary epithelial cells. Although crosstalk between IGF-1R signaling and
EGFR signaling is detectable in MCF10A cells, this crosstalk is not required for the IGF-1 mediated regulation of LIP
expression. Rather, the critical regulator of IGF-1 induced LIP expression appears to be EGFR-independent, Akt
activity. Our data also demonstrate that increases in LIP expression promote cell survival via suppression of anoikis.
Likewise, knockdown of total C/EBPb leads to increased cell death and suggest that C/EBPb expression is important
for survival and resistance to anoikis. IGF-1 treatment can partially rescue vector control cells from anoikis; however,
cells with reduced C/EBPb expression do not survive anoikis.
Conclusions: Taken together, our data demonstrate that IGF-1R signaling regulates LIP expression in an EGFR
independent manner to increase the LIP/LAP ratio in mammary epithelial cells. C/EBPb expression and elevations in
LIP play an important role in regulating cellular survival via suppression of anoikis, in an IGF-1R mediated context
or in a manner independent of IGF-1R signaling.
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Background
The transcription factor, CCAAT/Enhancer binding pro-
tein b (C/EBPb) is an important mediator of mammary
development [1,2] and breast tumorigenesis [3,4].
Encoded by an intronless gene, C/EBPb is expressed as
several distinct protein isoforms (LAP1, LAP2 and LIP)
whose expression is tightly regulated by the differential
use of a number of in-frame translation start sites [5-7].
All of the C/EBPb isoforms share the same C-terminal
DNA binding and leucine zipper dimerization domains,
but LIP lacks all of the N-terminal transactivation
domain and much of the inhibitory domains. Conse-
quently, LIP can act as a dominant-negative [5] to inhi-
bit gene transcription or as an activator of transcription,
depending upon the nature of its interaction with other
C/EBP family members and transcription factors [8-11].
T h eL I Pa n dL A Pi s o f o r m sm a yt h u sh a v ep o t e n t i a l l y
opposing actions in cellular proliferation and differentia-
tion and increases in the LIP/LAP ratio are known to be
associated with tumorigenesis and metastasis. For
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gland leads to hyperplasia and tumor formation [12]. In
humans, the LIP isoform is strongly expressed in a per-
centage of aggressive human breast tumors that are
estrogen receptor negative, aneuploid, highly prolifera-
tive and associated with a poor prognosis [13,14]. In
metastatic breast cancer cells, an increase in the LIP/
LAP ratio has been linked to a loss in the TGFb-depen-
d e n tc y t o s t a t i cr e s p o n s ea n dam o r ea g g r e s s i v ep h e n o -
type [15]. The C/EBPb isoforms thereby play an
important role in high grade, metastatic breast cancer
and the LIP/LAP ratio is a critical determinant in the
aggressiveness of the disease.
It is therefore imperative, that we better understand
the molecular mechanisms regulating LIP expression
and the biological significance of the LIP/LAP ratio in
breast cancer. Growth factor signaling pathways, such as
the insulin-like growth factor-1 receptor (IGF-1R) [16]
and the epidermal growth factor receptor (EGFR) signal-
ing cascades [17] have been implicated in the develop-
ment of aggressive, metastatic breast cancer. IGF-1R
signaling contributes to breast cancer progression and
recurrence in part by increasing cell survival via
mechanisms that include suppression of anoikis [18-21].
Anoikis is an induction of apoptosis that occurs in cells
upon loss of cellular adhesion and is one of the hall-
m a r k so fm e t a s t a s i s[ 2 2 ] .C / E B P b has also been shown
to play a role in cell survival; specifically, of hepatic cells
[23], keratinocytes [24], and macrophages [25], but has
not yet been associated with suppression of anoikis.
Moreover, it is also not known whether LIP plays a spe-
cific role to increase the survival of breast cancer cells.
To better understand the molecular mechanisms that
regulate LIP expression in metastatic breast cancer, we
set out to determine in mammary epithelial cells
whether IGF-1R signaling leads to an increase in LIP
expression and whether LIP plays a role in IGF-1R
mediated suppression of anoikis.
Numerous studies have demonstrated that the actions
of IGF-1R are linked to that of EGFR in epithelial mam-
mary cells to synergistically drive cellular proliferation
[26-30]. Additional reports have characterized a relation-
ship between IGF-1R and EGFR signaling in aggressive,
drug-resistant breast cancer cells and have speculated
that IGF-1R signaling plays a role in the development of
gefitinib resistant EGFR tumors [31]. Because our pre-
vious study [32], demonstrated that LIP expression is
increased by EGFR signaling, this led us to question,
and to address in this study whether IGF-1R signaling
can solely regulate LIP expression and whether crosstalk
and activation of the EGF receptor is required. Along
these lines, a recent study showed how changes in the
LIP/LAP ratio downstream of HER2 provide evasion to
oncogene induced senescence and TGFb cytostasis [33].
These authors showed that changes in LIP/LAP ratio, in
an AKT dependent manner, support evasion of a tumor
suppressor mechanism in metastatic breast cancer cells
[33]. Similarly, an earlier study demonstrated that HER2
expression can lead to survival from anoikis in MCF10
and HMEC cells [34].
Our data demonstrate that IGF-1R signaling regulates
LIP expression in an EGFR independent manner to
increase LIP expression and the LIP/LAP ratio in mam-
mary epithelial cells. Although crosstalk between IGF-
1R signaling and EGFR signaling is detectable in
MCF10A cells, this crosstalk is not required for the
IGF-1 mediated regulation of LIP expression. Rather,
the critical regulator of IGF-1 induced LIP expression
appears to be EGFR-independent, Akt activity. Our data
also demonstrate that a biological action of LIP is to
increase cell survival by suppression of anoikis which
may occur in either an IGF-1R mediated context or in a
manner independent of IGF-1R signaling. Taken
together, the accumulated evidence discussed above, as
well as our current data suggest that LIP expression
may be an important downstream target of EGFR,
ErbB2 and IGF-1R signaling in breast cancer.
Results
IGF-1R increases the ratio of LIP/LAP expression
To determine whether IGF-1 regulates C/EBPb-LIP
expression in mammary epithelial cells, MCF10A cells
were serum starved for 24 hours and then stimulated
with IGF-1 (2.6 nM, 20 ng/ml) for 4 or 16 hours prior
to harvesting. Western blot analysis of whole cell
extracts demonstrated that treatment with IGF-1 led to
an increase in the LIP isoform (Figure. 1A). The LIP iso-
form was more significantly elevated as compared to the
LAP isoforms, resulting in a statistically significant
increase in the LIP/LAP ratio of 3.5 fold (p < 0.05) after
16 hrs of treatment as compared to LIP/LAP levels
observed in serum starved, non-treated cells (Figure
1A). Similar increases in LIP expression and the LIP/
LAP ratio were observed in MCF 7 cells treated with 2.6
nM IGF-1 for 16 hours (Figure 1B). Treatment of cells
with insulin (10 nM) also led to increases in LIP protein
expression (Figure 1A). The identification and sizes of
the human LAP 1 and LAP 2 isoforms were confirmed
in our previous study [32].
An IGF-1 concentration of 2.6 nM was chosen for this
study because it is within the Kd of the IGF-1 receptor,
and will not result in activation of the insulin receptor
[35,36]. In some experiments the IGF-1 concentration
was increased 15× to 39 nM in order to generate a max-
imal LIP induction due to activation of IGF-1R, hybrid
receptors and the insulin receptor. Likewise an insulin
concentration of 10 nM activates insulin receptors but
not IGF-1 receptors [35,36]. Because a strong induction
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Page 2 of 14Figure 1 Stimulation of MCF10A and MCF7 cells with IGF-1 leads to an increase in LIP expression and the LIP/LAP ratio, but not in LIP
mRNA expression. A). Western blot analysis of MCF10A cells serum starved for 24 hours prior to 4, or 16 hours of treatment with IGF-1 (2.6 nM)
or insulin (10 nM). Whole cell extracts (100 μg) were analyzed via 12% SDS-PAGE and Western blotting using a monoclonal anti-C/EBPb
antibody. b-actin was used to estimate loading and transfer of proteins. The western blot shown is representative of dozens of separate Western
blots. The LIP/LAP ratio was quantitated using Li-COR’s Odyssey infrared imaging system. LAP1 and LAP2 expression values were combined and
normalized to GAPDH. LIP values were also normalized to GAPDH. The fold change in the LIP/LAP ratio from the IGF-1 treated cells vs. the
control cells was calculated and statistical significance was determined via an unpaired, 2-tailed T test with a * p value < 0.05. n = 4. B). Western
blot analysis of MCF7 cells serum starved for 24 hours prior to 16 hours of treatment with IGF-1 (2.6 nM). The fold change and statistical
significance in the LIP/LAP ratio was studied as Figure 1A (n = 5). C-D). MCF10A and MCF7 cells were treated with IGF-1 for 16 hours. Total RNA
was extracted and quantitative realtime PCR was conducted with specific C/EBPb mRNA primers. No obvious difference was observed in C/EBPb
mRNA expression between untreated and IGF-1 treated cells. (MCF10A; n = 3) (MCF 7; n = 6).
Li et al. Molecular Cancer 2011, 10:100
http://www.molecular-cancer.com/content/10/1/100
Page 3 of 14in LIP expression was commonly observed 16 hr after
IGF-1 treatment, this time point was selected for all
consequent analyses in this study.
IGF-1R does not regulate C/EBPb mRNA
To determine whether the increase in LIP expression
might be the result of transcriptional increases in C/
EBPb mRNA, RNA was purified from IGF-1 (2.6 nM)
treated MCF10A and MCF7 cells and C/EBPb mRNA
expression levels were analyzed by real-time qPCR. No
statistically significant changes were observed in the
levels of C/EBPb mRNA in response to a 16 hour treat-
ment of cells with 2.6 nM IGF-1 (Figure 1C, D). These
data suggest that IGF-1R signaling does not increase C/
EBPb-LIP expression via an increase in C/EBPb mRNA
transcription, but rather via post-transcriptional
mechanisms.
IGF-1R regulates C/EBPb activity
It was next important to determine whether the
increased expression of LIP and the elevations observed
in the LIP/LAP ratio in response to IGF-1 treatment
were biologically active. To serve as a control, we first
validated the activity of the individual LIP and LAP2
constructs on a C/EBPb responsive promoter as shown
in Figure 2A. C/EBPb null mammary epithelial cells
were transfected with either LIP, or LAP2 individually
or together with a C/EBP responsive, firefly luciferase
construct and renilla luciferase construct as control. As
expected, LAP2 expression led to an increase in C/EBP
responsive luciferase activity while LIP alone reduced
promoter activity (Figure 2A). In combination with
LAP2, LIP expression antagonized and decreased LAP2
induced promoter activity and led to a decrease in luci-
ferase activity. To test for IGF-1 induced, endogenous
C/EBPb activity, MCF10A cells were transfected with a
C/EBP responsive, luciferase construct before stimula-
tion with IGF-1. To maximize LIP expression for a sig-
nificant increase the LIP/LAP ratio, cells were
stimulated for 16 hrs with 39 nM IGF-1. This led to an
expected decrease in C/EBP responsive luciferase activity
due to the antagonistic effects of increased LIP expres-
sion (Figure 2B). These data demonstrate that IGF-1R
induced increases in the LIP/LAP ratio are biologically
active.
Does IGF-1R and Insulin regulate LIP expression via the
activation of the EGF receptor?
Because IGF-1R signaling has been observed to cross-
talk with EGFR signaling, it was necessary to determine
whether the IGF-1R induced expression of LIP was, in
part, mediated by EGFR signaling. We therefore investi-
gated whether treatment of MCF10A and MCF7 cells
with IGF-1 leads to phosphorylation of EGFR. As deter-
mined by Western blot analysis, neither IGF-1 nor insu-
lin stimulation led to a significant increase in EGFR
Figure 2 IGF-1 stimulates the inhibitory effect on a C/EBP consensus construct. A). To validate the activity of individual LIP and LAP2
constructs, a C/EBP consensus luciferase construct (500 ng) and a Renilla construct (20 ng) as internal control were co-transfected with LAP2
and LIP individually or together at different ratios into C/EBPb null cells to a total of 2500 ng plasmid DNA. Control vector serves as both a
control for basal activity and to match the quantity of plasmid DNA. Luciferase and Renilla activities were recorded at 48 hours. B). IGF-1
stimulation of MCF10A cells regulates C/EBPb activity. MCF10A cells were transfected with a C/EBP consensus Luciferase construct (500 ng) and a
Renilla construct (20 ng) as internal control and serum starved for 24 hours prior to treatment with 39 nM IGF-1. Luciferase activity was analyzed
after 16 hours of treatment with IGF-1. The relative luciferase activity was calculated as Luciferase value/Renilla value (n = 5). Statistical
significance was determined using an unpaired, 2-tailed T-test with a * p value < 0.05.
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extracts 10 minutes (Figure 3A) after addition of ligand.
Additionally, neither a 10× increase in IGF-1 nor insulin
activated the EGF receptor (Figure 3A). However,
immunoprecipitation followed by immunoblot analysis
did show a modest increase in phosphorylated EGFR
after 10 minutes of IGF-1 stimulation (Figure 3B).
In addition to IGF-1 and insulin receptors, mammary
epithelial cells can also express insulin/IGF-1 hybrid
receptors [36-38]. Hybrid receptors have been detected
in most tissues that express both insulin receptor and
IGF-1 receptor. An IGF-1 concentration of 2.6 nM will
not activate the insulin receptor, but could potentially
lead to the activation of the insulin/IGF 1 hybrid recep-
tors. Data presented in Figure 3C supports this hypoth-
esis and suggests that IGF-1 (2.6 nM) signaling has led
to the formation of insulin/IGF-1 hybrid receptors.
Functional studies with hybrid receptors demonstrate
that they behave more like IGF-1 receptors rather than
insulin receptors because they bind IGF-1 with a much
better affinity than insulin [37,38]. As expected, we did
not observe activation of the hybrid receptor with 10
nM insulin (Figure 3C). Although the significance of the
hybrid receptors in mammary epithelial cells in unclear,
we hypothesize that the insulin/IGF-1 hybrids may be
more abundant in MCF10A cells than otherwise
expected and this hypothesisi ss u p p o r t e db yr e p o r t s
that insulin and hybrid insulin/IGF -1 receptors are
important regulators of breast cancer cells [36,38].
Throughout this study, we will refer to the IGF-1R
mediated induction in LIP for simplicity, but the reader
should understand that hybrid receptors may also be
involved in regulation of LIP/LAP.
Because LIP expression is analyzed 16 hr after addi-
tion of ligand, we also checked p-EGFR expression at
this later time point. EGFR was not phosphorylated in
MCF10A cells or MCF 7 cells 16 hr after addition of
IGF-1 (Figure 3D, E) To confirm that IGF-1 was indeed
activating the IGF-1R signaling cascade, we analyzed p-
IGF-1R and p-Akt expression at 20 min and 16 hr (Fig-
ure 3D, E).
To further assess the possibility that EGFR activity
may play a role in the IGF-1R stimulated increase in
LIP expression, we tested the sensitivity of IGF-1 treated
MCF10A cells to the selective EGFR kinase inhibitor,
AG1478. Pretreatment of cells for 30 minutes with 0.1,
1o r5μM AG1478 prior to addition of 2.6 nM IGF-1
for 16 hr did not inhibit or reduce the IGF-1 mediated
increases in LIP expression and did not inhibit the
increase in the LIP/LAP ratio (Figure 4A left portion &
4B). As a control, 5 μMA G 1 4 7 8d i dl e a dt ot h e
expected decrease in p-EGFR (Figure 4A, lower panel),
decreases in EGF mediated LIP expression and the LIP/
LAP ratio, and lesser reductions with 0.1 and 1 μM
(Figure 4A right portion). Treatment of cells with 0.1,
and 1.0 μM AG1478 effectively reduced IGF-1-induced
Erk1/2 phosphorylation (Figure 4C left panel) and as
expected EGF-induced Erk1/2 phosphorylation (Figure
4C right panel). These data demonstrate that inhibition
of EGFR kinase activity reduces IGF-1R mediated Erk1/
2 activity and suggest that IGF-1R and EGFR signaling
crosstalk in MCF10As to regulate Erk1/2 activity (as
suggested in Figure 3B). Our data also demonstrate that
inhibition of EGFR signaling with AG1478 does not
inhibit IGF-1R induced Akt activity but does block EGF
induced Akt activity (Figure 4C). These data are in
agreement with published results and demonstrate that
IGF-1R mediated Akt activity is not regulated by EGFR
signaling, and that IGF-1R mediated Erk1/2 activity is
ErbB dependent [26]. IGF-1R mediated Akt activity thus
appears to be an important regulator of IGF-1R
induced-LIP expression and may also be important for
EGF mediated LIP expression.
To validate that IGF-1R induced LIP expression is
EGFR independent, we tested an additional EGFR inhi-
bitor. IGF-1R induced LIP expression was not reduced
by treatment of MCF10A cells with the EGFR specific,
monoclonal antibody, mAb528, which blocks the ligand
epitope binding site of EGFR. Although this antibody
blockade had no affect on IGF-1R induced LIP expres-
sion or the LIP/LAP ratio, it did reduce EGF-induced
LIP expression, and the LIP/LAP ratio as expected (Fig-
ure 4D). Taken together, these data suggest that
although EGFR signaling can crosstalk with IGF-1R sig-
naling, the crosstalk is not required for the IGF-1R
mediated regulation of LIP expression in MCF10A cells.
The role of ERK1/2, and Akt activity in the regulation of
IGF-1R induced C/EBPb-LIP expression
To better understand the importance of p44/42 MAPK
(Erk1/2) and phosphatidylinositol 3-kinase (PI3K)/ser-
ine-threonine protein kinase B (Akt) in the regulation of
IGF-1R induced LIP expression, cells were pre-treated
with a Mek1/2 inhibitor, (U0126), or an Akt inhibitor,
(SH-6), 30 minutes prior to stimulation with 2.6 nM
IGF-1. As anticipated, 5 and 10 μM U0126 effectively
inhibited the IGF-1R induced phosphorylation of Erk1/2
but did not inhibit Akt phosphorylation or the increase
observed in LIP expression and the LIP/LAP ratio (Fig-
ure 5A). Treatment of MCF10A and MCF7 cells with
SH-6, which acts to prevent membrane localization of
Akt by competing with Inositol (3, 4, 5) phosphate bind-
ing to the Akt pleckstrin homology domain [39], effec-
tively reduced p-Akt expression and LIP expression in
IGF-1 treated cells and led to a reduction in the LIP/
LAP ratio (Figure 5B, C). Taken together, these results
suggest that Akt activity is an important regulator of
IGF-1R induced LIP expression.
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Page 5 of 14Figure 3 IGF-1 signaling weakly activates EGFR. Western blot analysis of serum starved MCF10A and MCF7 cells stimulated with insulin (10 or
100 nM), IGF-1 (2.6 or 26 nM) or EGF (1.6 or 16 nM) for 10-20 minutes or 16 hours and harvested for analysis of phosphorylation status for the
EGFR, IGF-1R, insulin receptor, Akt, or Erk1/2. A). MCF10A whole cell protein extracts, 100 μg for phospho-EGFR (p-EGFR) and 50 μg for total EGFR
(EGFR) were analyzed via 7% SDS-PAGE and Western Blotting using anti-EGFR antibodies. B). Upper panel: 1-2 mg of whole cell extracts were
immunoprecipitated overnight with anti-EGFR, electrophoresed via 7% SDS-PAGE and immunoblotted with anti-phosphotyrosine (4G10). Lower
panel: Whole cell extracts (WCE 50 μg) analyzed via 7% SDS-PAGE and Western Blotting using anti-EGFR antibody. C). Whole cell extracts were
immunoprecipitated with 4G10 and immunoblotted with anti IGF-1R or anti-insulin receptor. D). Whole cell protein extracts of MCF10A, 100 μg
were analyzed via 7% SDS-PAGE and Western Blotting using specific antibodies to p-EGFR, p-IGF-1R, total EGFR (EGFR), p-Akt, p-Erk1/2, total Akt
or total Erk1/2. E). Whole cell protein extracts of MCF7, 100 μg were analyzed via 7% SDS-PAGE and Western Blotting using specific antibodies to
p-EGFR, p-IGF-1R, total EGFR (EGFR) and p-Akt, p-Erk1/2, total Akt or total Erk1/2.
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Page 6 of 14C/EBPb expression is important for cell survival following
anoikis
To better understand the biological significance of C/
EBPb expression in response to IGF-1R signaling, we
investigated how knock down of C/EBPb expression
affects the well established, anti-apoptotic role of IGF-
1R in cell survival. Anoikis, which is an induction of
apoptosis that occurs upon loss of cellular adhesion
[22], was induced in MCF10A cells via forced suspen-
sion culture on low adherence plates for up to 96 hrs,
and apoptosis was analyzed as a sub-G1 fraction or
Annexin V staining by flowcytometry (Figure 6A, B, C).
Treatment of cells that were serum starved for 24 hrs
prior to anoikis, with 39 nM IGF-1, led to an expected
increase in cell survival as shown by a significant
decrease in apoptosis and reduction in the percent of
vector control cells in sub-G1 from 2.5% to 1.5% at 48
hr (bars 3 & 4) and from 9% to 6% at 96 hr (bars 7 & 8)
of treatment (Figure 6A). Treatment of cells with 2.6
nM IGF-1 led to similar results (data not shown). It is
Figure 4 Pharmacological blockade of EGFR does not inhibit IGF-1 induced increases in LIP expression. MCF10A cells were serum-starved
for 24 hrs, pretreated for 30-60 min with inhibitors, and stimulated with ligands for 10 min or 16 hours. A). Western blot analysis demonstrating
that pretreatment of cells with the EGFR inhibitor, AG1478, does not prevent IGF-1R induced LIP expression at 16 hrs, but does antagonize EGF
induced LIP expression at doses of 0.1, 1, and 5 μM as compared to control cells stimulated with EGF but without AG1478 treatment (0). The
functionality of AG1478 was confirmed by Western blot using a p-EGFR antibody (lower panel). B). LIP/LAPs ratio in MCF10A cells stimulated with
IGF-1 and treated with AG1478 as in (A) was quantitated using an Odyssey infrared imaging system. No significant decrease of IGF-1R induced
LIP expression or LIP/LAPs ratio was observed with AG1478 treatment at 16 hours as determined via a two-tailed T-test (n = 3). C). Western blot
demonstrating that increasing doses of AG1478 (0.1-1 μM) can inhibit EGF induced phosphorylation of Erk1/2 and Akt, and the IGF induced
phosphorylation of Erk1/2, but AG1478 has no effect on IGF-1R activated phosphorylation of Akt. Total Erk1/2 and Akt served as loading controls.
D). Western blot analysis demonstrates that treatment with mAb528 only blocks the EGF induced LIP expression, p-Akt, and p-Erk1/2. There is no
obvious effect on IGF-1R induced LIP expression, p-Akt, or p-Erk1/2.
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vector control cells into the anoikis assay, we checked
duplicate plates of cells to validate IGF-1R induced LIP
expression. Because the C/EBPb isoforms are translated
from a single mRNA, it is not possible to selectively
knock down the individual LIP and LAP isoforms; how-
ever successful knockdown of total C/EBPb expression
with shRNA (Figure 6E) led to decreases in cell survival.
Increased apoptosis, as observed by the increased num-
ber of cells in sub-G1 as compared to vector control
rose from 2.5% to 5.1% at 48 hr (bars 3 & 5) and 9% to
22% at 96 hr (bars 7 & 9) in the cells with knocked
down C/EBPb expression (Figure 6A). Moreover, in the
presence of knocked-down C/EBPb expression, IGF-1
treatment only moderately increased survival, with
decreases in apoptosis from 5.1% to 4% at 48 hr (bars 5
& 6) and 22% to 16% at 96 hr (bars 9 & 10). These
decreases in apoptosis were not statistically significant.
Because we have demonstrated in this study that IGF-
1R signaling increases LIP expression and the ratio of
LIP/LAP, we sought to test the effects of LIP overex-
pression on survival from anoikis, in a manner similar
to that described in Figure 6A. Overexpression of LIP in
MCF10A cells was accomplished using a pEIZ (HIV-
Zsgreen) lentiviral construct driven by the EF-alpha 1
promoter [40]. Overexpression of LIP (Figure 6F) led to
decreases in apoptosis as evidenced by the number of
Annexin V positive cells (Figure 6B) and the accumula-
tion of cells in sub-G1 at both 48 hr and 96 hr of anoi-
kis (Figure 6C). These data suggest that the LIP isoform
has an anti-apoptotic action and plays a role in cellular
survival of anoikis. Thus the biological consequence of
IGF-1R mediated increases in LIP expression may
include the actions of LIP to participate in the regula-
tion of cell survival. Our data demonstrate that treat-
ment of cells with IGF-1 or overexpression of LIP leads
to decreases in the percentage of cells in sub-G1, and
decreases in the number of cells positive for Annexin V,
thus representing a decrease in apoptosis (Figure 6A, B,
C).
Taken together, the data in Figure 6 demonstrate that
C/EBPb knockdown leads to increased cell death and an
accumulation of cells in sub-G1 and suggest that C/
EBPb expression is important for survival and resistance
to anoikis. Furthermore, we showed that IGF-1R treat-
ment can partially rescue control cells from anoikis;
however, cells with reduced C/EBPb expression, are not
successfully rescued from anoikis. This is most clearly
observed in clonogenic outgrowth assays of C/EBPb
knock-down cells (Figure 6D). Suspension culture of
vector control and C/EBPb knock-down cells, in the
presence of IGF-1 for 24 hr, followed by harvest and
subsequent plating for adherent growth revealed a dra-
matic reduction in the survival and clonogenic activity
of cells with knocked down C/EBPb expression (Figure
6D). Similarly, overexpression of LIP reduced anoikis, as
evidenced by the decreased number of Annexin V posi-
tive cells and the decreased number of sub G1 cells. In
summary, C/EBPb expression appears to play an impor-
tant role in protection from anoikis and may be an inte-
gral downstream mediator of the protective effects of
IGF-1R signaling.
Figure 5 Akt, but not Erk1/2, is important for IGF-1R mediated regulation of LIP expression. A). Western blot analysis demonstrating that
pretreatment of MCF10A cells with the MEK inhibitor U0126 (5 and 10 μM) blocks IGF-1R activated phosophorylation of Erk1/2, but not
phosphorylation of Akt at 10 min. IGF-1R mediated increases in LIP expression were not inhibited by 16 hour of treatment with U0126. Similar
results were observed in > 3 independent experiments. B, C). Increasing doses of the Akt inhibitor, SH-6 (1-5 μM), prior to stimulation of cells
with IGF-1 (2.6 nM) leads to an inhibition of Akt activity and results in decreased LIP expression at 16 hours in both MCF10A (B) and MCF7 (C)
cells. The LIP/LAP ratio is provided.
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Page 8 of 14Figure 6 C/EBPb expression is important for cell survival following anoikis. A). Flow cytometry of MCF10A cells in forced suspension
culture at 48 hr and 96 hr. Cell death was analyzed by measuring the sub-G1 cell cycle fraction. Vector control (Vector) and C/EBPb knock down
(shRNA) cells were treated with Doxycycline (1 μg/ml) for 2 days to activate shRNA expression, followed by one more day of Dox treatment in
serum free conditions. IGF-1 (I), (2.6 nM or 39 nM) was then added to the treated cultures at time 0 hour. n = 3B). Flow cytometry of Annexin V
positive MCF10A cells, that were transduced to overexpress LIP in forced suspension culture for 24 and 48 hours. n = 3. C). Anoikis assay of
MCF10A cells transduced with lenti-LIP (LIP) or vector control (vector) and cultured in suspension for 48 and 96 hours prior to Flow cytometry
for the sub G1 cell cycle fraction. Statistical significance was determined using an unpaired, 2-tailed T-test with a * p value < 0.05. n = 3. D). After
24 hours of suspension culture in serum free media containing IGF-1 (39 nM), vector control or C/EBPb knock down cells were transferred to
standard 6 well cell culture plates and permitted to adhere and expand for two weeks for analysis of clonogenic outgrowth potential followed
by staining with crystal violet. E-F). Western blot analysis of MCF10A cells with shRNA knock down for C/EBPb (E) or transduced to overexpress
LIP (F).
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tion of mammary epithelial cells leads to increased
expression of LIP and an elevation in the LIP/LAP ratio.
We additionally demonstrate that IGF-1R induced-LIP
expression is biologically active as determined on a C/
EBP responsive promoter construct. Although IGF-1R
signaling can crosstalk with EGFR signaling to regulate
Erk1/2 activity in our study, IGF-1R induced LIP expres-
sion is independent of EGFR signaling. We demonstrate
that Akt activity is a critical determinant in the regula-
tion of IGF-1R induced LIP expression and that EGFR-
dependent, Erk1/2 activity is not necessary for IGF-1R
induced LIP expression. Lastly we show that LIP plays a
role to increase the survival of cells from anoikis and
may participate in IGF-1R mediated suppression of
anoikis.
Discussion
Our data, as well as that from others, suggest that onco-
genic signaling pathways such as IGF-1R, EGFR [32],
and ErbB2 [33] regulate increases in LIP expression and
the LIP/LAP ratio. IGF-1R, EGFR and ErbB2 and are
also critical regulators of tumorigenesis and can regulate
cellular survival of anoikis [34,41]. IGF-1R signaling is
known to play an important role in the resistance of
cells to apoptosis and this anti-apoptotic effect is most
strongly observed during anchorage-independent condi-
tions (reviewed in [42] and in metastatic breast cancer
cells [43,44] The survival of cells in suspension, or the
ability to suppress anoikis, is a critical step in the pro-
gression of invasive cancer because metastatic cells must
survive under anchorage-independent conditions as they
move from the primary tumor to distant sites. The
molecular mechanisms that regulate anoikis in invasive
cancer cells are poorly understood, but we have demon-
s t r a t e dt h a tl o s so fC / E B P b expression renders cells
more susceptible to anoikis, even in the presence of
IGF-1R signaling. Moreover, LIP overexpression protects
cells from anoikis. Our study is the first to document a
role for C/EBPb in the survival of mammary epithelial
cells under anchorage-independent growth conditions.
The biological significance of elevated LIP expression as
a consequence of IGF-1R receptor signaling holds
important implications for the LIP/LAP ratio as a criti-
cal mediator of anchorage-independent growth in breast
cancer.
Taken together, C/EBPb-LIP appears to be an impor-
tant downstream target for EGFR, ErbB2 and IGF-1R
signaling, and particpates in the regulation cell survival
and apoptosis. This survival mechanism may actually be
quite universal and not unique to breast cells. For exam-
ple, macrophages require C/EBPb for survival in
response to Myc/Raf transformation [25] and hepatic
stellate cells that are DNA damaged via CCl4 induced
free radical formation [23] also need C/EBPb for survi-
val. In keratinocytes that have suffered DNA damage, C/
EBPb promotes cell survival by reducing p53 expression
and activity [45]. Reduced levels of C/EBPb can thereby
sensitize cells to apoptosis and this has been observed
both in our anoikis model (Figure 6A) and in C/EBPb
null mice which display resistance to DMBA-induced
skin tumorigenesis [24].
Numerous parallels exist between the biological effects
of IGF-1R signaling and that of LIP overexpression. For
instance, both the IGF-1/insulin receptor families and
the C/EBPb isoforms play important roles in cellular
processes that regulate mammary development and
breast cancer such as cell cycle control, proliferation,
and differentiation. As an example, cell cycle entry and
progression to the restriction point in late G1 is con-
trolled by growth factors, such as IGF-1; however the C/
EBPb isoforms also interact with or regulate similar cell
cycle proteins such as p53 [46], Rb [47,48] CDK2, cyclin
A, cyclin E [49] cyclin D1 [50] p21Cip1, [51], and
p15INK4b [15].
In regards to development, inhibition of IGF-1R sig-
naling or knockdown of C/EBPb expression disrupts
mammary gland development. For example, mammary
gland development is restricted in both IGF-1 null mice
[52] and in IGF-1R-null mice [53]. Similar phenotypes
are observed in the C/EBPb null mouse, where deletion
of the C/EBPb isoforms leads to defective mammary
gland development and reduced milk production [1,2].
Conversely, the activation or elevation of IGF-1R or LIP
expression induces mammary proliferation and tumori-
genesis. For example, overexpression of IGF-1R in the
mouse mammary gland leads to tumorigenesis [54-58]
while in a similar fashion, transgenic expression of LIP
in mouse mammary glands induces hyperproliferation
and tumorigenesis [12].
Moreover, in women, elevated LIP or IGF-1R expres-
sion are independently associated with breast cancer.
Approximately 23% of aggressive breast cancers contain
elevated LIP and this increase in LIP is associated with
reduced estrogen and progesterone receptor expression
and an otherwise poor prognosis [13]. Both the IGF-1R
and insulin receptor are activated and expressed at ele-
vated levels in breast cancer [16,59]. In fact, patients
with type 2 diabetes mellitus are suspected to be at
increased risk of developing breast cancer [60]. When
considering the fact that LIP expression is regulated by
IGF-1R signaling, and that numerous biological similari-
ties exist between LIP overexpression and IGF-1R sig-
naling, one can only speculate that LIP may in part, be
a critical mediator of many of the downstream effects of
IGF-1R signaling
Although our study focused on the IGF-1R regulation
of LIP and LAP expression; the reverse has also been
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shown to be regulated by the LIP and LAP isoforms in
macrophages, hepatocytes, and osteoblasts (Reviewed in
[4]). With the exception of our current study in the
mammary epithelial cell line MCF10A, little is known
about IGF-1 and LIP/LAP interactions in breast epithe-
lial cells. In bone marrow derived macrophages isolated
from the C/EBPb K/O mouse, IGF-1 expression is mod-
erately decreased in response to the loss of C/EBPb
expression [25]. Similarly, in hepatocytes, the addition of
C/EBPb-LAP in the human hepatoma cell line Hep3B
increases IGF-1 expression [61]. Overexpression of LIP
alone appears to have no effect on IGF-1 promoter
activity, but does abolish the transactivation induced by
LAP [61]. Moreover, C/EBPb is believed to play a role
in the proliferation and differentiation of osteoblasts via
regulation of IGF-1 and studies have shown that the
protein levels and DNA binding activity of the C/EBPb
isoforms, LAP1, LAP2 and LIP are elevated in proliferat-
ing osteoblasts (MC3T3-E1 cells) and down regulated
upon differentiation [62]. In light of these studies and
our recent data, we speculate that the C/EBPb-LIP and
LAP isoforms participate in a feedback loop to regulate
IGF-1 signaling; however, this hypothesis will require
further experimentation.
Conclusions
Previously we demonstrated in MCF10As that EGFR
signaling increases expression of the C/EBPb-LIP iso-
form and that this regulation is dependent upon Erk1/2
activity [32]. We now show that IGF-1 and insulin sig-
naling regulate LIP expression in MCF10A cells, and
that Akt activity, rather than Erk1/2 is a critical determi-
nant for IGF-1R induced LIP expression. In some cellu-
lar contexts, cross talk has been shown to occur
between the IGF-1 receptor and the EGF receptor
(EGFR) during mediation of IGF-1 signaling
[26,27,29,63]. The mechanism of crosstalk may involve
the IGF-1 stimulated cleavage and solubilization of
EGFR pro-ligands which lead to EGFR activation [26] or
the direct interaction of IGF-1R with EGFR to form
EGFR-IGF-1R hetero-oligomers [29]. Regardless of the
mechanism at work in our study, crosstalk between
IGF-1 and EGFR is not necessary for the regulation of
LIP expression by IGF-1. The reasons for this may be
explained by the observation that PI3K/Akt pathway
and Ras/Erk1/2 pathways downstream of IGF-1 signal-
ing are often functionally dissociated [26,29]. IGF-1
induced Erk1/2 activity can be predominantly activated
by the transactivation of EGFR in response to IGF-1
while Akt activation is independent of EGFR activity
[26,29]. Our data clearly show that IGF-1 mediated
increases in LIP expression are not regulated by EGFR
dependent Erk1/2 activity, but rather by IGF-1 induced
Akt activity. The mechanism by which Akt activates LIP
translation and expression remain to be elucidated.
Methods
Cell Culture
Cultured mammary epithelial cells, MCF10A, were grown
in Dulbecco modified Eagle medium (DMEM)-F12 (Invi-
trogen, USA) supplemented with 5% donor horse serum
(Invitrogen, USA), 20 ng/ml of recombinant human EGF
(Invitrogen, USA), 10 μg/ml of bovine pancreatic insulin
(Sigma, USA), 100 ng/ml of cholera toxin (Sigma, USA),
0.5 μg/ml of hydrocortisone (Sigma, USA), and 5 μg/ml of
gentamycin sulfate (Invitrogen, USA). MCF7 cells were
g r o w ni nE a g l e ’s Minimum Essential Medium (MEM)
(Mediatech, USA) supplemented with 0.01 mg/ml bovine
insulin and 10% fetal bovine serum (Hyclone, USA). C/
EBPb null cells were culture in Hepes buffered, Dulbecco
modified Eagle medium (DMEM)-F12 (Invitrogen, USA)
supplemented with 2% adult bovine serum (Invitrogen,
USA), 5 ng/ml of recombinant human EGF (Invitrogen,
USA), 10 μg/ml of bovine pancreatic insulin (Sigma, USA)
and 5 μg/ml gentamycin sulfate.
Suspension Culture/Anoikis Assay
To knock down C/EBPb expression, C/EBPb (Tet-On)
and control TRIPZ™lentiviral shRNAmir constructs
(Open Biosystem, USA) were stably transduced into
MCF-10A cells by infection and puromycin selection.
Prior to suspension culture, the cells were treated with
Doxycycline (1 μg/ml) for 2 days to activate shRNA
expression, followed by one more day of Dox treatment
in serum free conditions to synchronize the cells and to
generate a maximal knockdown of C/EBPb expression.
To prevent adherence, cells were transferred to Costar 6
well ultra low attachment plates (20,000 cells/well) or to
1% agar coated plates (500,000 cells/10 cm dish) for 24,
48 and 96 hrs in the presence or absence of IGF-1 (2.6
nM and 39 nM). After 24 hrs, suspended cells were
transferred to standard 6 well cell culture plates and
permitted to adhere to analyze survival via clonogenic
outgrowth for two weeks followed by staining with crys-
tal violet. Flow cytometry was conducted on cells col-
lected at 48 and 96 hrs of suspension culture. Briefly,
suspended cells were collected by centrifuge at 1000
rpm for 5 min. To prevent clustering, cells were
digested in 1× trypsin at 37°C for 5 min, followed by
washing with HBSS. Cells were then resuspended in
(0.6% NP-40, 3.7% Formalin, 11% Hoechst 33258 in
PBS) for Flow cytometry. Cell death was analyzed by
measuring the sub-G1 cell cycle fraction. LIP was over-
expressed in MCF-10A cells using a pEIZ (HIV-Zsgreen)
lentiviral construct driven by the EF-alpha 1 promoter
(kindly provided by Dr. Zena Werb [40]) and cells were
sorted. Annexin V-PE Apoptosis detection kit was
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ing to manufacturer’s instructions.
Cell Treatment, Protein Isolation and ECL Western Blot
Analysis
MCF10A and MCF7cells were plated at a density of 1.7 ×
10
6/100 mm and upon reaching 75 to 80% confluency,
the growth medium was removed and replaced with a
serum-free, defined medium containing DMEM-F12, 100
ng/ml cholera toxin, 0.5 μg/ml of hydrocortisone, and 5
μg/ml of gentamycin sulfate for MCF10A, and MEM for
MCF7. Cells were maintained in defined medium for 24
hour prior to the addition of ligand: human EGF (Invitro-
gen, USA), IGF-1 (Sigma, USA), insulin (Sigma, USA)
and harvested at 10-20 min or 16 hr after the addition of
ligand. The MEK inhibitor, U0126 (Calbiochem, USA),
the Akt inhibitor, SH-6 (Axxora Platform, USA), the
EGFR inhibitor, AG1478 (Sigma, USA), and the blocking
antibody EGFR-mAb528 (Santa Cruz Biotechnology,
USA) were added 30-60 min before addition of ligand.
Cells harvested at 16 hr were sonicated in radioimmuno-
precipitation assay (RIPA) buffer (50 mM Tris-HCl [pH
7.4], 1% NP-40, 0.25% deoxycholate, 150 mM NaCl, 10
mM EGTA, 0.2% sodium dodecyl sulfate [SDS]) contain-
ing a protease inhibitor cocktail (Sigma, USA) and a
phosphatase inhibitor I and II mixture (Sigma, USA). Ali-
q u o t so ft h el y s a t e sc o n t a i n i n g1 0 0 - 2 0 0μgo fp r o t e i n
were boiled at 100°C for 10 min, electrophoresed on
denaturing SDS-7% or 12% polyacrylamide minigels, and
then transferred to polyvinylidene difluoride membranes
(PVDF, Millipore, Bedford, Mass. USA). Blots were
blocked 1-2 hr in TBST (20 mM Tris [pH 7.5], 150 mM
NaCl, 0.5% Tween 20) containing 5% Carnation dry milk
and then incubated with prima r ya n t i b o d yf o r1 - 2h r( o r
overnight for antibodies directed against phospho-pro-
teins) in TBST-1-5% carnation milk. Primary antibodies
used were monoclonal and polyclonal anti-C/EBPb
(1:250, Santa Cruz, USA), polyclonal anti-GAPDH
(1:5000, Trevigen, Gaithersburg, MD, USA), polyclonal
b-actin (1:1000 Santa Cruz, USA), monoclonal anti-phos-
pho-p44/42 (1:2000, Cell Signaling, Beverly, MA, USA),
polyclonal anti-p44/42 (1:2000, Cell Signaling, USA),
monoclonal anti-phospho Akt, polyclonal Akt (1:1000,
Cell Signaling, USA), polyclonal anti-EGFR (1:1000 Santa
Cruz, USA), monoclonal anti-phospho-EGFR (Tyr 845,
1:1000, Cell Signaling, USA). Blots were washed with
TBST three times for 5 to 10 min each with agitation and
then incubated for 1 hr with either goat anti-mouse-
horseradish peroxidase (HRP) conjugate (Santa Cruz.
USA) or goat-anti-rabbit-HRP (Bio-Rad, Hercules, CA,
USA) in TBST-1-5% carnation. Proteins were visualized
by either DURA or FEMTO chemiluminescence (Super
Signal; Pierce, Rockford, Ill. USA) and HyBlot CL film
(Denville Scientific, Metuchen, NJ, USA). Blots were
stripped in Re-blot Plus Mild Solution (Chemicon, Teme-
cula, CA, USA) for reprobing.
Western Blot Analysis Using Odyssey Infrared Imaging
Proteins were electrophoresed and transferred to PVDF
membranes as described above. Membranes were
blocked for 1 hr in Odyssey blocking buffer. Primary
antibodies (1:250, monoclonal anti-C/EBPb,S a n t aC r u z ,
USA), polyclonal anti-GAPDH (1:5000, Trevigen,
Gaithersburg, MD, USA) and secondary antibodies
(1:5000, goat anti-mouse IR Dye 800 CW, LI-COR Bios-
ciences and 1:5000, goat anti-mouse IR Dye 680 DX, LI-
COR, USA) were diluted in blocking buffer with 0.1%
Tween-20 and incubated with the blot for 1 hr at room
temperature. After washing, the membranes were
scanned using Li-COR’s Odyssey infrared imaging sys-
tem and quantitated using Odyssey 3 software.
Quantitative Realtime PCR
MCF10A and MCF7cells were plated at a density of 75
to 80% confluency, the growth medium was removed
and replaced with a serum-free, defined mediums as
described. Cells were maintained in defined medium for
24 hour prior to the addition of human IGF-1 (Sigma,
USA) and harvested at 16 hr after the addition of ligand
b ya d d i n g1m lT r i z o l( I n v i t r o g e n ,U S A ) .T o t a lR N A
was extracted according to the manufacturer’si n s t r u c -
tion. First-strand cDNA was prepared with 5 μgt o t a l
RNA, random primers and reverse transcriptase (Super-
Script II RNase H, Invitrogen, USA) according to the
manufacturer’s instruction. Quantitative PCR was per-
formed by using real-time PCR iCycler (Bio-Rad, USA).
PCR reaction and C/EBPb primers were: sense 5’
AACTCTCTGCTTCTCCCTCTG 3’;a n t i s e n s e
5’AAGCCCGTAGGAACATCTTT 3’.C tv a l u e sw e r e
converted to relative expression using the delta-delta Ct
method, allowing normalization to both 18S and
untreated control. The primer sequences for 18S were
sense 5’ GTAACCCGTTGAACCCCATTC 3’; antisense:
CCATCCAATCGGTAGTAGCG 3’.
Luciferase Assay
To validate the activity of individual LIP and LAP2 con-
structs, a C/EBP consensus luciferase construct (500 ng)
and a Renilla construct (20 ng) as internal control were
cotransfected with LAP2 and LIP individually or
together at different ratios into C/EBPb null cells to a
total of 2500 ng plasmid DNA. Control vector serves as
both a control for basal activity and to match the quan-
tity of plasmid DNA. Luciferase and Renilla activities
were recorded at 48 hrs. For the IGF experiment, MCF-
10A cells were cultured in Falcon 24-well plates and at
70% confluency, were transfected with a C/EBP consen-
sus Luciferase construct (500 ng) and a Renilla construct
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using Fugene reagent (Roche, Switzerland, according to
manufacturer instructions) and cells were maintained in
serum free medium for 24 hrs. The cells were then trea-
ted with 2.6 nM IGF-1 for 16 hrs in serum free medium
and luciferase activity was analyzed at the end of treat-
ment. The relative luciferase activity was calculated as
Luciferase value/Renilla value. n = 5
Immunoprecipitation and Immuno-Blot Analysis of EGFR
MCF10A cells incubated with ligand for 10 min were
extracted in RIPA buffer without SDS, and sonicated.
Protein extracts (1 mg) were pre-cleared for 1 hr at 4°C
with protein G-PLUS agarose (Santa Cruz, USA), then
immunoprecipitated overnight at 4°C with anti-EGFR
(1:1000, Santa Cruz, USA) or 4G10-conjugated agarose
beads (Upstate Biotechnology, Waltham, MA, USA) to
immunoprecipitate IGF-1R/IR. The beads were rinsed 3
times with RIPA (without SDS), sample buffer was
added, the mixture boiled for 10 minutes followed by
electrophoresis through SDS-7% polyacrylamide minigels,
and transfer to PVDF. Immuno-blots were performed as
above using anti-phospho-EGFR (1:1000, Cell Signaling,
USA), anti-IR (1:1000 Upstate Biotechnology, USA) or
anti-IGF-1R (1:1000 Upstate Biotechnology, USA).
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